Ligand Pharmaceuticals has raised its Q3 2023 revenue forecast to a range of $126M-$129M, which is higher than the previous estimate of $126.5M and the prior range of $124M-$126M. This upward revision indicates that the company expects better financial performance, which could lead to a positive investor sentiment and potentially boost its stock price in the short term.